The primary endpoint ( combined rate of cerebral neurological events , systemic thromboembolism , all-cause death and major bleeding events ) occurred in 3 of 174 ( 1.7 % ) patients on fondaparinux and 2 of 170 ( 1.2 % ) patients on UFH+VKA .